Return to CBI Antibody Core Home Page
  Return to human list
    Return to human ( Homo sapiens ) list


human ( Homo sapiens )
LRPPRC



Western result: +
GST
GST-LRPPRC
(fragment)

38 kDa (recombinant)
The western blot contains a test lane of ~20ug of a total protein extract from E coli with ~50ng to 500ng of the antigen (GST-antigen fusion protein). The negative control lane is the same except it contains ~50ng to 100 ng of a GST fusion protein of an irrelevant antigen. The blot was probed with a final antisera dilution of 1:1,000. The secondary antibody (Rabbit anti-mouse IgG + IgM, (H+L) horseradish peroxidase conjugated (Pierce)) is used at 1:5,000 dilution. Note, the molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used and it is fused to GST.

Antibody Name/Abbreviation: LRPPRC
CBI Antibody Core Code: A0682

"Lot" Number: 1 Position: 100(897-996)
% Identical Homology of Target to Mouse Protein: 87% (NP_082509.1| leucine-rich PPR motif-containing protein; leucine rich protein LRP130)
Molecular Weight of fusion protein: 38 KDa

Target sequence used to make this antibody:
AFLQTGNYKEAKKIIETPGIRARSARLQWFCDRCVANNQV
ETLEKLVELTQKLFECDRDQMYYNLLKLYKINGDWQRADA
VWNKIQEENVIPREKTLRLL






Sequence Name: LRPPRC
Full name: leucine-rich PPR motif-containing protein
UniGene Number: N.A.
Accession Number: NP_573566
Source organism: human ( Homo sapiens )
Full length size (aa): 1394
NCBI information page: click here

Full length sequence:
MAALLRSARWLLRAGAAPRLPLSLRLLPGGPGRLHAASYLPAARAGPVAG
GLLSPARLYAIAAKEKDIQEESTFSSRKISNQFDWALMRLDLSVRRTGRI
PKKLLQKVFNDTCRSGGLGGSHALLLLRSCGSLLPELKLEERTEFAHRIW
DTLQKLGAVYDVSHYNALLKVYLQNEYKFSPTDFLAKMEEANIQPNRVTY
QRLIASYCNVGDIEGASKILGFMKTKDLPVTEAVFSALVTGHARAGDMEN
AENILTVMRDAGIEPGPDTYLALLNAYAEKGDIDHVKQTLEKVEKSELHL
MDRDLLQIIFSFSKAGYPQYVSEILEKVTCERRYIPDAMNLILLLVTEKL
EDVALQILLACPVSKEDGPSVFGSFFLQHCVTMNTPVEKLTDYCKKLKEV
QMHSFPLQFTLHCALLANKTDLAKALMKAVKEEGFPIRPHYFWPLLVGRR
KEKNVQGIIEILKGMQELGVHPDQETYTDYVIPCFDSVNSARAILQENGC
LSDSDMFSQAGLRSEAANGNLDFVLSFLKSNTLPISLQSIRSSLLLGFRR
SMNINLWSEITELLYKDGRYCQEPRGPTEAVGYFLYNLIDSMSDSEVQAK
EEHLRQYFHQLEKMNVKIPENIYRGIRNLLESYHVPELIKDAHLLVESKN
LDFQKTVQLTSSELESTLETLKAENQPIRDVLKQLILVLCSEENMQKALE
LKAKYESDMVTGGYAALINLCCRHDKVEDALNLKEEFDRLDSSAVLDTGK
YVGLVRVLAKHGKLQDAINILKEMKEKDVLIKDTTALSFFHMLNGAALRG
EIETVKQLHEAIVTLGLAEPSTNISFPLVTVHLEKGDLSTALEVAIDCYE
KYKVLPRIHDVLCKLVEKGETDLIQKAMDFVSQEQGEMVMLYDLFFAFLQ
TGNYKEAKKIIETPGIRARSARLQWFCDRCVANNQVETLEKLVELTQKLF
ECDRDQMYYNLLKLYKINGDWQRADAVWNKIQEENVIPREKTLRLLAEIL
REGNQEVPFDVPELWYEDEKHSLNSSSASTTEPDFQKDILIACRLNQKKG
AYDIFLNAKEQNIVFNAETYSNLIKLLMSEDYFTQAMEVKAFAETHIKGF
TLNDAANSRLIITQVRRDYLKEAVTTLKTVLDQQQTPSRLAVTRVIQALA
MKGDVENIEVVQKMLNGLEDSIGLSKMVFINNIALAQIKNNNIDAAIENI
ENMLTSENKVIEPQYFGLAYLFRKVIEEQLEPAVEKISIMAERLANQFAI
YKPVTDFFLQLVDAGKVDDARALLQRCGAIAEQTPILLLFLLRNSRKQGK
ASTVKSVLELIPELNEKEEAYNSLMKSYVSEKDVTSAKALYEHLTAKNTK
LDDLFLKRYASLLKYAGEPVPFIEPPESFEFYAQQLRKLRENSS





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.